{
    "nctId": "NCT00574587",
    "briefTitle": "Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy",
    "officialTitle": "Phase I-II Trial of Vorinostat Plus Weekly Paclitaxel (+/- Trastuzumab) Followed by Doxorubicin-cyclophosphamide in Patients With Locally Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 55,
    "primaryOutcomeMeasure": "Recommended Phase II Dose of Vorinostat in Combination With Weekly Paclitaxel/Trastuzumab",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast associated with the following stages: IIB, IIIA, IIIB or IIIC.\n* Tumor must be Her2/neu positive\n* No prior chemotherapy, radiation or definitive therapeutic surgery\n\nExclusion Criteria:\n\n* May not be receiving any other investigational agents\n* Uncontrolled intercurrent illness",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}